Gemfibrozil is a potent lipid regulating drug whose major effects are to increase plasma high density lipoproteins (HDL) and to decrease plasma triglycerides (TG) in a wide variety of primary and secondary dyslipoproteinemias. Its mechanism of action is not clear. Six patients with primary familial endogenous hypertriglyceridemia with fasting chylomicronemia (type V lipoprotein phenotype) with concurrent subnormal HDL cholesterol levels (HDL deficiency) were treated initially by diet and once stabilized, were given gemfibrozil (1,200 mg/d). Each patient was admitted to the Clinical Research Center with metabolic kitchen facilities, for investigation of HDL and TG metabolism immediately before and after 8 wk of gemfibrozil treatment. Gemfibrozil significantly increased plasma HDL cholesterol, apolipoprotein (apo) AI, and apo AII by 36%, 29%, and 38% from base line, respectively. Plasma TG decreased by 54%. Kinetics of apo AI and apo AII metabolism were assessed by analysis of the specific radioactivity decay curves after injection of autologous HDL labeled with 125I. Gemfibrozil increased synthetic rates of apo AI and apo AII by 27% and 34%, respectively, without changing the fractional catabolic rates. Stimulation of apo AI and apo AII synthesis by gemfibrozil was associated with the appearance in plasma of smaller (and heavier) HDL particles as assessed by gradient gel electrophoresis and HDL composition. Postheparin extra-hepatic lipoprotein lipase activity increased significantly by 25% after gemfibrozil, and was associated with the appearance in plasma of smaller very low density lipoprotein particles whose apo CIII:CII ratio was decreased. These data suggest that gemfibrozil increases plasma HDL levels by stimulating their synthesis. Increased transport (turnover) of HDL induced by gemfibrozil may be significant in increasing tissue cholesterol removal in these patients.
K Saku, P S Gartside, B A Hynd, M L Kashyap
Title and authors | Publication | Year |
---|---|---|
Structural Analysis of Human Serum Albumin in Complex with the Fibrate Drug Gemfibrozil.
Liberi S, Linciano S, Moro G, De Toni L, Cendron L, Angelini A |
International journal of molecular sciences | 2022 |
Enhanced antihyperlipidemic potential of gemfibrozil under co-administration with piperine
S Mohanalakshmi, S Bhatt, CK Kumar |
2021 | |
Enhanced antihyperlipidemic potential of gemfibrozil under co-administration with piperine.
Mohanalakshmi S, Bhatt S, Ashok Kumar CK |
2021 | |
Pigments from Filamentous Ascomycetes for Combination Therapy
R Hromádka, Z Kejík, M Jakubek, R Kaplánek, V Šandriková, M Urban, P Martásek, V Král |
Current medicinal chemistry | 2019 |
Solubility measurement, Hansen solubility parameters and solution thermodynamics of gemfibrozil in different pharmaceutically used solvents
MA Kalam, S Alshehri, A Alshamsan, M Alkholief, R Ali, F Shakeel |
Drug Development and Industrial Pharmacy | 2019 |
Parental gemfibrozil exposure impacts zebrafish F1 offspring, but not subsequent generations
S Fraz, AH Lee, S Pollard, K Srinivasan, A Vermani, JY Wilson |
Aquatic toxicology (Amsterdam, Netherlands) | 2019 |
The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
F Hong, P Xu, Y Zhai |
International journal of molecular sciences | 2018 |
Impact of inorganic ions and pH variations on toxicity and endocrine potential of selected environmentally relevant pharmaceuticals
M Wieczerzak, B Kudłak, G Yotova, S Tsakovski, V Simeonov, J Namieśnik |
Environmental pollution (Barking, Essex : 1987) | 2018 |
Effects of Acetaminophen (Paracetamol) and Gemfibrozil on Seed Development and Antioxidant Enzyme Activities in Different Wheat Varieties
E Türkoğlu, E Osma, M Elveren |
IRAN J SCI TECHNOL A | 2017 |
Association of Serum Triglyceride Level and Gemfibrozil Consumption With Periodontal Status
F Sayar, N Akhondi, S Fallah, AA Moalemnia, A Cheraghi |
Journal of Periodontology | 2017 |
Sex difference between target levels of cholesterol-related parameters and post-PCI long-term clinical outcomes: From the FU-Registry
Y Matsuoka, A Ike, M Ogawa, K Gondo, K Shirai, M Sugihara, D Nose, H Nishikawa, A Iwata, A Kawamura, K Mori, B Zhang, S Yasunaga, S Miura, K Saku |
Journal of Cardiology | 2017 |
Intestinal nuclear receptors in HDL cholesterol metabolism
C Degirolamo, C Sabbà, A Moschetta |
Journal of lipid research | 2014 |
Therapeutic Approaches to the Regulation of Metabolism of High-Density Lipoprotein
B Zhang, E Kawachi, S Miura, Y Uehara, A Matsunaga, M Kuroki, K Saku |
Circulation journal : official journal of the Japanese Circulation Society | 2013 |
Advances in Dyslipidemia
D Soffer, M Schoen |
Advances in Dyslipidemia | 2013 |
Annual Reports in Medicinal Chemistry
JJ Liu, TW Lee |
Annual Reports in Medicinal Chemistry Volume 46 | 2011 |
High-Density Lipoprotein and Coronary Heart Disease
P Natarajan, KK Ray, CP Cannon |
Journal of the American College of Cardiology | 2010 |
The effect of PPAR-α agonism on apolipoprotein metabolism in humans
A Shah, DJ Rader, JS Millar |
Atherosclerosis | 2010 |
Raising HDL cholesterol in women
DJ Eapen, GL Kalra, L Rifai, CA Eapen, N Merchant, BV Khan |
International journal of women's health | 2010 |
Should We Take High-Density Lipoprotein Cholesterol Levels at Face Value?
JO Leite, ML Fernandez |
American Journal Cardiovascular Drugs | 2010 |
High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease
EJ Schaefer |
2010 | |
Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome
JS Millar, D Duffy, R Gadi, LA Bloedon, RL Dunbar, ML Wolfe, R Movva, A Shah, IV Fuki, M McCoy, CJ Harris, MD Wang, DC Howey, DJ Rader |
Arteriosclerosis, thrombosis, and vascular biology | 2009 |
Gemfibrozil, stretching arms beyond lipid lowering
A Roy, K Pahan |
Immunopharmacology and Immunotoxicology | 2009 |
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels
DJ Hausenloy, DM Yellon |
Current Opinion in Cardiology | 2009 |
Fibrates: where are we now?
RS Loomba, R Arora |
Therapeutic advances in cardiovascular disease | 2009 |
Cytochrome P450 — physiological key factor against cholesterol accumulation and the atherosclerotic vascular process
PV Luoma |
Annals of Medicine | 2007 |
Toxicological effects of the lipid regulator gemfibrozil in four aquatic systems
JL Zurita, G Repetto, Á Jos, M Salguero, M López-Artíguez, AM Cameán |
Aquatic Toxicology | 2007 |
High-Density Lipoprotein Cholesterol-Raising Strategies
JT Kuvin, AA Alsheikh-Ali, RH Karas |
Journal of Cardiovascular Pharmacology | 2006 |
Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans?: Fig. 1
S Rashid, BW Patterson, GF Lewis |
Journal of lipid research | 2006 |
Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins
B Zhang, H Tomura, A Kuwabara, T Kimura, S Miura, K Noda, F Okajima, K Saku |
Atherosclerosis | 2005 |
High-Density Lipoprotein Cholesterol and Coronary Heart Disease:
CE Young, RH Karas, JT Kuvin |
Cardiology in Review | 2004 |
Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies
DC Chan, PH Barrett, GF Watts |
The Clinical biochemist. Reviews / Australian Association of Clinical Biochemists | 2004 |
Dyslipidemia in the metabolic syndrome
DC Chan, GF Watts |
Journal of Drug Evaluation | 2004 |
Role of Fibric Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease:
JP Desprs, I Lemieux, SJ Robins |
Drugs | 2004 |
Optimal Therapy of Low Levels of High Density Lipoprotein-Cholesterol:
ML Kashyap, S Tavintharan, VS Kamanna |
American Journal Cardiovascular Drugs | 2003 |
Evaluation of apolipoprotein A-I kinetics in rabbits in vivo using in situ and exogenous radioiodination methods
B Zhang, E Shimoji, H Tanaka, K Saku |
Lipids | 2003 |
Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy
L Calza, R Manfredi, B Farneti, F Chiodo |
International Journal of Antimicrobial Agents | 2003 |
PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance
JE Klaunig, MA Babich, KP Baetcke, JC Cook, JC Corton, RM David, JG DeLuca, DY Lai, RH McKee, JM Peters, RA Roberts, PA Fenner-Crisp |
Critical Reviews in Toxicology | 2003 |
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
S Bilz, S Wagner, M Schmitz, A Bedynek, U Keller, T Demant |
Journal of lipid research | 2003 |
Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells
D Zhu, SH Ganji, VS Kamanna, ML Kashyap |
Atherosclerosis | 2002 |
Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients
MF Chen, TD Wang, HT Yeh, HC Hsu, YT Lee |
European Journal of Clinical Investigation | 2001 |
High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects
PP Toth |
Disease-a-Month | 2001 |
Lp A-I and Niacin: New Views of an Antiatherogenic Duo
L Saucan, EA Brinton |
Arteriosclerosis, thrombosis, and vascular biology | 2001 |
Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol
T Sakai, VS Kamanna, ML Kashyap |
Arteriosclerosis, thrombosis, and vascular biology | 2001 |
Albumin inhibits apolipoprotein AI and AII production in human hepatoblastoma cell line (Hep G2): additive effects of oleate–albumin complex
T Sakai, FY Jin, VS Kamanna, ML Kashyap |
Atherosclerosis | 2000 |
HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia
K Winkler, JR Schaefer, B Klima, C Nuber, I Friedrich, W Köster, H Gierens, H Scharnagl, M Soufi, H Wieland, W März |
Atherosclerosis | 2000 |
Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
KH Mayer, MP Dube, D Sprecher, WK Henry, JA Aberg, FJ Torriani, HN Hodis, J Schouten, J Levin, G Myers, R Zackin, T Nevin, JS Currier |
Clinical Infectious Diseases | 2000 |
Age-associated decrease in plasma cholesterol and changes in cholesterol metabolism in homozygous watanabe heritable hyperlipidemic rabbits
M Shiomi, T Ito, T Fujioka, Y Tsujita |
Metabolism | 2000 |
Preventing, stopping, or reversing coronary artery disease— triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: The need for recognition and treatment
EE Ferguson |
Disease-a-Month | 2000 |
In Vivo Metabolism of HDL, Apo A-I, and Lp A-I, and Function of HDL -A Clinical Perspective
B Zhang, K Saku, T Ohta |
Journal of Atherosclerosis and Thrombosis | 2000 |
In vivo kinetics of human apolipoprotein A-I variants in rabbits
Saku, von Eckardstein, Zhang, Liu, Jimi, Ou, Ohta, Assmann, Arakawa |
European Journal of Clinical Investigation | 1999 |
Combined Effects of Probucol and Bezafibrate on Lipoprotein Metabolism and Liver Cholesteryl Ester Transfer Protein mRNA in Cholesterol-Fed Rabbits
J Ou, K Saku, S Jimi, YL Liao, T Ohta, B Zhang, K Arakawa |
Japanese Circulation Journal | 1999 |
Effect of gemfibrozil on triacylglycerol synthesis and secretion by liver and lipoprotein lipase activity in adipose tissue of rats
K Nagao, M Sakono, M Nakayama, T Hirakawa, K Imaizumi |
Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology | 1999 |
The regulation of Acetyl-CoA carboxylase—a potential target for the action of hypolipidemic agents
MR Munday, CJ Hemingway |
Advances in Enzyme Regulation | 1999 |
Developmental and Pharmacological Regulation of Apolipoprotein C-II Gene Expression: Comparison With Apo C-I and Apo C-III Gene Regulation
Y Andersson, Z Majd, AM Lefebvre, G Martin, AV Sechkin, V Kosykh, JC Fruchart, J Najib, B Staels |
Arteriosclerosis, thrombosis, and vascular biology | 1999 |
Decrease in High Density Lipoprotein Cholesterol (HDL-C) Levels Following Gemfibrozil Therapy
AG Lacko, BJ Kudchodkar, WW Loney, MB Clearfield, S Weis |
Clinical Chemistry and Laboratory Medicine | 1998 |
No Effect of Fibrates on Synthesis of Apolipoprotein(a) in Primary Cultures of Cynomolgus Monkey and Human Hepatocytes: Apolipoprotein A-I Synthesis Increased
DM Neele, A Kaptein, H Huisman, EC de Wit, HM Princen |
Biochemical and Biophysical Research Communications | 1998 |
Principles of Medical Biology
JO Jørgensen |
Principles of Medical Biology | 1998 |
Mechanistic studies of high-density lipoproteins
ML Kashyap |
The American Journal of Cardiology | 1998 |
Treatment of Diabetic Dyslipidemia
AG MD |
The American Journal of Cardiology | 1998 |
Mechanism of action of probucol on cholesteryl ester transfer protein (CETP) mRNA in a Chinese hamster ovary cell line that had been stably transfected with a human CETP gene
J Ou, K Saku, S Jimi, T Ohta, B Zhang, HJ Pownall, Y Shimada, Y Tsujita, K Arakawa |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1998 |
Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet
K Nagao, S Yoshida, H Nakagiri, M Sakono, M Sato, K Imaizumi |
Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology | 1998 |
The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates
N Vu-Dac, S Chopin-Delannoy, P Gervois, E Bonnelye, G Martin, JC Fruchart, V Laudet, B Staels |
The Journal of biological chemistry | 1998 |
Estradiol Stimulates Apolipoprotein A-I– but Not A-II–Containing Particle Synthesis and Secretion by Stimulating mRNA Transcription Rate in Hep G2 Cells
FY Jin, VS Kamanna, ML Kashyap |
Arteriosclerosis, thrombosis, and vascular biology | 1998 |
Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates):
DB Miller, JD Spence |
Clinical Pharmacokinetics | 1998 |
Gene Activation, Apolipoprotein A-I/High Density Lipoprotein, Atherosclerosis Prevention and Longevity
PV Luoma |
Pharmacology & Toxicology | 1997 |
A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India
HO Sharma, SK Sharma |
Indian Journal of Clinical Biochemistry | 1997 |
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery
M Syvänne, MR Taskinen, MS Nieminen, V Manninen, YA Kesäniemi, A Pasternack, JW Nawrocki, H Haber, MH Frick |
Controlled Clinical Trials | 1997 |
Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells: Implication for Reverse Cholesterol Transport
FY Jin, VS Kamanna, ML Kashyap |
Arteriosclerosis, thrombosis, and vascular biology | 1997 |
Mechanism of the slow induction of apolipoprotein A-I synthesis by retinoids in cynomolgus hepatocytes: involvement of retinoic acid and retinoid X receptors
A Kaptein, DM Neele, J Twisk, HF Hendriks, T Kooistra, HM Princen |
Journal of lipid research | 1997 |
Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia
CY Yang, ZW Gu, YH Xie, NV Valentinova, M Yang, D Yeshurun, JA Quion, AM Gotto |
Atherosclerosis | 1996 |
Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels
EJ Schaefer, S Lamon-Fava, T Cole, DL Sprecher, DD Cilla, CC Balagtas, JP Rowan, DM Black |
Atherosclerosis | 1996 |
Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats
BR Krause, BC Barnett, AD Essenburg, KA Kieft, BJ Auerbach, R Bousley, R Stanfield, RS Newton, CL Bisgaier |
Atherosclerosis | 1996 |
Cytochrome P450 and atherosclerosis
P Luoma |
Clinical Pharmacology & Therapeutics | 1996 |
HDL Heterogeneity and Atherosclerosis
A Tailleux, JC Fruchart, JG Parkes |
Critical Reviews in Clinical Laboratory Sciences | 1996 |
Protein-DNA Interactions at a Drug-responsive Element of the Human Apolipoprotein A-I Gene
X Zhang, ZQ Chen, Z Wang, W Mohan, SP Tam |
The Journal of biological chemistry | 1996 |
Gemfibrozil Stimulates Apolipoprotein A-I Synthesis and Secretion by Stabilization of mRNA Transcripts in Human Hepatoblastoma Cell Line (Hep G2)
FY Jin, VS Kamanna, MY Chuang, K Morgan, ML Kashyap |
Arteriosclerosis, thrombosis, and vascular biology | 1996 |
Drugs Affecting Lipid Metabolism
AM Gotto, R Paoletti, LC Smith, AL Catapano, AS Jackson |
1996 | |
Age-Related Changes Affecting Atherosclerotic Risk: Potential for Pharmacological Intervention
LG Spagnoli, A Mauriello, A Orlandi, G Sangiorgi, E Bonanno |
Drugs & Aging | 1996 |
The effects of probucol and clofibrate alone and in combination on hepatic cholesterol metabolism in the male rat
J Shand |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1995 |
Effects of Acipimox on the metabolism of free fatty acids and very low density lipoprotein triglyceride
JS Hannah, NL Bodkin, MS Paidi, N Anh-Le, BV Howard, BC Hansen |
Acta Diabetologica | 1995 |
Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients
J Kahri, T Sane, A Tol, MR Taskinen |
Journal of Internal Medicine | 1995 |
Section Review—Cardiovascular & Renal: Emerging Therapies in Atherosclerosis
BR Krause, DR Sliskovic, TM Bocan |
Expert Opinion on Investigational Drugs | 1995 |
Bezafibrate therapy in patients with isolated low high-density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis
MS Weintraub, I Grosskopf, G Charach, R Mor, A Rubinstein, Y Wollman, R Judevices, A Iaina |
Metabolism | 1995 |
Multiple Risk Factors in Cardiovascular Disease
AM Gotto, C Lenfant, AL Catapano, R Paoletti |
1995 | |
A New Case of ApoA-I Deficiency Showing Codon 8 Nonsense Mutation of the ApoA-I Gene Without Evidence of Coronary Heart Disease
K Takata, K Saku, T Ohta, M Takata, H Bai, S Jimi, R Liu, H Sato, G Kajiyama, K Arakawa |
Arteriosclerosis, thrombosis, and vascular biology | 1995 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors
G Schonfeld |
Atherosclerosis | 1994 |
Primary care of the renal transplant patient
JD Pirsch, R Friedman |
Journal of General Internal Medicine | 1994 |
Association of high density lipoprotein with whole blood-associated acetaldehyde levels
MR Halvorson, JK Noffsinger, BD Roberts, CM Peterson |
Alcohol | 1994 |
Drug control of reverse cholesterol transport
G Franceschini, JP werba, L Calabresi |
Pharmacology & Therapeutics | 1994 |
Combined Treatment with Pravastatin and Gemfibrozil in Patients with Refractory Familial Combined Hyperlipidaemia: A Clinical Study
VG Athyros, AA Papageorgiou, HJ Hagikonstantinou, GV Papadopoulos, CX Zamboulis, AG Kontopoulos |
Drug Investigation | 1994 |
7 Dyslipidaemia and obesity
JP Després |
Baillière's Clinical Endocrinology and Metabolism | 1994 |
Principles and Treatment of Lipoprotein Disorders
G Schettler, AJ Habenicht |
1994 | |
Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome
IE Sitno, JA Yakichuk, TC Ooi |
Atherosclerosis | 1993 |
Drugs controlling triglyceride metabolism
G Franceschini, R Paoletti |
Medicinal Research Reviews | 1993 |
Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity
J Kahri, H Vuorinen-Markkola, M Tilly-Kiesi, S Lahdenperä, MR Taskinen |
Atherosclerosis | 1993 |
Gemfibrozil increases apolipoprotein A-I and cholesterol concentrations in human peripheral lymph
D Reichl, NE Miller, JM Sterchi |
European Journal of Clinical Investigation | 1993 |
Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase
RB Simsolo, JM Ong, PA Kern |
Metabolism | 1993 |
In vivo conversion of recombinant human proapolipoprotein AI (rh-Met-proapo AI) to apolipoprotein AI in rabbits
K Saku, R Liu, K Ohkubo, H Bai, K Hirata, K Yamamoto, Y Morimoto, K Yamada, K Arakawa |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1993 |
Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus
M Syvänne, H Vuorinen-Markkola, H Hilden, MR Taskinen |
Arteriosclerosis Thrombosis and Vascular Biology | 1993 |
Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia
C Contacos, PJ Barter, DR Sullivan |
Arteriosclerosis Thrombosis and Vascular Biology | 1993 |
Ethanol stimulates apolipoprotein A-I secretion by human hepatocytes: Implications for a mechanism for atherosclerosis protection
RN Amarasuriya, AK Gupta, M Civen, YC Horng, T Maeda, ML Kashyap |
Metabolism | 1992 |
Postprandial Lipoprotein Metabolism in Obese Patients with Moderate Hypertriglyceridaemia: Effects of Gemfibrozil
HH Ditschuneit, M Flechtner-Mors, E Hagel, H Ditschuneit |
J INT MED RES | 1992 |
Mode of action of fibrates
AL Catapano |
Pharmacological research : the official journal of the Italian Pharmacological Society | 1992 |
Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia
KJ Williams, KA Petrie, RW Brocia, TL Swenson |
Journal of Clinical Investigation | 1991 |
Gemfibrozil in familial combined hyperlipidaemia: effect of added low-dose cholestyramine on plasma and biliary lipids
B Ödman, S Ericsson, M Lindmark, L Berglund, B Angelin |
European Journal of Clinical Investigation | 1991 |
Fibrates and triglyceride metabolism
P Schwandt |
European Journal of Clinical Pharmacology | 1991 |
Effects of Gemfibrozil and Other Fibric Acid Derivatives on Blood Lipids and Lipoproteins
P Zimetbaum, WH Frishman, S Kahn |
The Journal of Clinical Pharmacology | 1991 |
Lipids and Women’s Health
GP Redmond |
1991 | |
Cerebral Ischemia and Dementia
A Hartmann, W Kuschinsky, S Hoyer |
1991 | |
A Comparative Review of the Adverse Effects of Treatments for Hyperlipidaemia:
A Steiner, B Weisser, W Vetter |
Drug Safety | 1991 |
Management of the patient with a low HDL-cholesterol
RF Leighton |
Clinical Cardiology | 1990 |
Effect of gemfibrozil on the concentration and composition of serum lipoproteins A controlled study with special reference to initial triglyceride levels
M Mänttäri, P Koskinen, V Manninen, JK Huttunen, MH Frick, EA Nikkilä |
Atherosclerosis | 1990 |
Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia
P Pauciullo, G Marotta, P Rubba, C Cortese, MG Caruso, A Gnasso, A Fischetti, C Motti, M Mancini |
Journal of Internal Medicine | 1990 |
Metabolic regulation of apoproteins of high-density lipoproteins by estrogen and progesterone in the baboon (Papio sp)
RS Kushwaha, DM Foster, VN Murthy, KD Carey, MG Bernard |
Metabolism | 1990 |
Raising high density lipoprotein cholesterol
NE Miller |
Biochemical Pharmacology | 1990 |
Putative mechanisms of action of probucol on high-density lipoprotein apolipoprotein A-I and its isoproteins kinetics in rabbits
H Ying, K Saku, R Harada, N Takami, N Sasaki, Y Saito, K Arakawa |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1990 |
6 Hyperlipidaemia and hypertension
W Krone, D Müller-Wieland |
Baillière's Clinical Endocrinology and Metabolism | 1990 |
Effect of Gemfibrozil Administration on Biliary Lipid Secretion in Hyperlipidemic Patients
G Mazzella, F Bazzoli, N Villanova, P Simoni, D Festi, A Roda, R Aldini, E Roda |
Scandinavian Journal of Gastroenterology | 1990 |
Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, in Vivo Kinetics
CL Malmendier, P Alaupovic, HB Brewer |
1990 | |
Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women
EA Brinton, S Eisenberg, JL Breslow |
Journal of Clinical Investigation | 1989 |
Guar gum and gemfibrozil — an effective combination in the treatment of hypercholesterolaemia
J Tuomilehto, M Silvasti, V Manninen, M Uusitupa, A Aro |
Atherosclerosis | 1989 |
Low-dose colestipol plus fenofibrate: Effects on plasma liproproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia
P Weisweiler |
Metabolism | 1989 |
Basic considerations in the reversal of atherosclerosis: Significance of high-density lipoprotein in stimulating reverse cholesterol transport
ML Kashyap |
The American Journal of Cardiology | 1989 |
Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism
D Reichl, NE Miller |
Arteriosclerosis (Dallas, Tex.) | 1989 |
Effects of fibrates on serum lipids and atherosclerosis
CR Sirtori, G Franceschini |
Pharmacology & Therapeutics | 1988 |
Apolipoproteins in human biopsied nephrotic kidneys
K Saku, T Sata, S Naito, K Fukushima, S Takebayashi, K Arakawa |
International Urology and Nephrology | 1988 |
Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia
SW Rabkin, M Hayden, J Frohlich |
Atherosclerosis | 1988 |
Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease
PT Kuo, AC Wilson, JB Kostis, AB Moreyra, HT Dodge |
American Heart Journal | 1988 |
Lessons from the Helsinki Heart Study: Fibric acid therapy for dyslipidemia
SM Grundy |
Postgraduate Medicine | 1988 |
Focus on Fenofibrate
WV Brown |
Hospital Practice | 1988 |
Treatment of Lipid Disorders in Diabetes Mellitus
FL Dunn |
Medical Clinics of North America | 1988 |
Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins
NA Le, JC Gibson, HN Ginsberg |
Journal of lipid research | 1988 |
Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil
MS Weintraub, S Eisenberg, JL Breslow |
Journal of Clinical Investigation | 1987 |
Pharmacological treatment of lipid disorders in diabetes mellitus
MF Lopes-Virella, JA Colwell |
Diabetes / Metabolism Reviews | 1987 |
Fibric acids: Effects on lipids and lipoprotein metabolism
SM Grundy, GL Vega |
The American Journal of Medicine | 1987 |
Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives
HN Ginsberg |
The American Journal of Medicine | 1987 |
High-density lipoprotein turnover
PJ Nestel |
American Heart Journal | 1987 |
10 Mode of action of lipid-lowering drugs
R Fears |
Baillière's Clinical Endocrinology and Metabolism | 1987 |
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
MH Frick, O Elo, K Haapa, OP Heinonen, P Heinsalmi, P Helo, JK Huttunen, P Kaitaniemi, P Koskinen, V Manninen, H Mäenpää, M Mälkönen, M Mänttäri, S Norola, A Pasternack, J Pikkarainen, M Romo, T Sjöblom, EA Nikkilä |
New England Journal of Medicine | 1987 |
Lipid-Lowering Drugs: An Overview of Indications and Optimum Therapeutic Use
DR Illingworth |
Drugs | 1987 |
Gemfibrozil increases both apo A-I and apo E concentrations
BR Krause, RS Newton |
Atherosclerosis | 1986 |